Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Amortization of Deferred Charges: 2024-2025

Historic Amortization of Deferred Charges for Lifecore Biomedical (LFCR) over the last 2 years, with May 2025 value amounting to $20.2 million.

  • Lifecore Biomedical's Amortization of Deferred Charges rose 12.68% to $6.8 million in Q2 2025 from the same period last year, while for May 2025 it was $20.2 million, marking a year-over-year increase of 31.12%. This contributed to the annual value of $20.2 million for FY2025, which is 31.12% up from last year.
  • As of FY2025, Lifecore Biomedical's Amortization of Deferred Charges stood at $20.2 million, which was up 31.12% from $15.4 million recorded in FY2024.
  • Lifecore Biomedical's 5-year Amortization of Deferred Charges high stood at $20.2 million for FY2025, and its period low was $15.4 million during FY2024.
  • Moreover, its 2-year median value for Amortization of Deferred Charges was $17.8 million (2024), whereas its average is $17.8 million.
  • Data for Lifecore Biomedical's Amortization of Deferred Charges shows a peak YoY surged of 31.12% (in 2025) over the last 5 years.
  • Lifecore Biomedical's Amortization of Deferred Charges (Yearly) stood at $15.4 million in 2024, then skyrocketed by 31.12% to $20.2 million in 2025.